Chinese President Xi Jinping and Uruguay's President Yamandú Orsi have elevated their strategic partnership, signing a raft of new agreements. The meeting, emphasizing an "equal and orderly multipolar world," underscores China's diplomatic push in Latin America following recent regional instability.
China becomes the first nation to regulate against concealed automotive door handles, a feature popularized by Tesla and adopted by other EV makers, citing safety concerns in emergency situations. The new standards take effect in 2027.
After a sharp recent pullback, Palantir Technologies' lofty valuation is under the microscope. While its long-term growth narrative remains compelling, traditional metrics suggest the stock may be pricing in near-perfect execution. We examine the numbers behind the debate.
Vaxcyte's shares have surged over 23% in the past month, sparking debate among investors. While a discounted cash flow model suggests significant upside, traditional metrics paint a more cautious picture. We examine the numbers and the narratives driving this biotech stock.
AT&T makes two significant strategic moves, acquiring Lumen's fiber assets to expand its broadband footprint and partnering to launch a network-based fall detection device for seniors, as it seeks to leverage its core infrastructure for future growth.
Coca-Cola shares have gained nearly 9% in the past month, buoyed by anticipation of its upcoming earnings report and a looming leadership transition. Analysts are divided on whether the iconic beverage giant's current valuation fully reflects its steady dividends and global brand strength.
Keysight Technologies' shares have climbed sharply, gaining 26.6% over the past year. As the stock trades near $223, investors are grappling with a critical question: does its current price reflect its true value, or has momentum pushed it into overvalued territory? A deep dive into key valuation metrics suggests caution may be warranted.
Shares of USA Rare Earth (USAR) have skyrocketed over 56% in the past month, defying its reported zero revenue and substantial losses. As the critical minerals sector heats up, investors are left to question whether this is speculative frenzy or a bet on a strategic national resource.
The U.S. Food and Drug Administration has removed a clinical hold on Intellia Therapeutics' pivotal Phase 3 study of its gene-editing candidate for a rare, progressive disease, allowing the trial to proceed with enhanced safety monitoring. The move refocuses investor attention on the company's pipeline and long-term valuation prospects.
Elon Musk's consolidation of SpaceX and xAI into a single tech giant brings renewed scrutiny to its substantial bitcoin treasury, raising questions about accounting, volatility, and investor strategy as the company eyes a public listing.
The board of the London-listed payments firm has unanimously rejected a revised $1.15-per-share offer from a consortium led by Helios Investment Partners, calling the bid 'highly opportunistic' and failing to reflect the company's future prospects.
Stoneridge, Inc. has completed the sale of its Control Devices segment to private equity firm Center Rock Capital Partners for $59 million. The move is part of a strategic pivot to strengthen its balance sheet and concentrate resources on advanced vision, safety, and connectivity technologies for commercial vehicles.
Amidst a downturn fueled by weak Chinese trade data and falling commodity prices, analysts identify a cluster of London-listed equities trading significantly below their intrinsic value, presenting potential opportunities for patient investors.
The distinctive buzz over Ukrainian trenches increasingly originates not from military superpowers, but from nations like Cyprus, with a population of just over one million. The war has catalyzed a continent-wide surge in indigenous, high-tech defense production, reshaping Europe's strategic landscape.
A brief humanitarian pause brokered by the U.S. collapsed as Russia launched fresh attacks on Ukrainian cities, targeting energy infrastructure during a severe cold snap that has seen temperatures plummet below -20°C.
Indonesia is launching a massive state-owned textile enterprise backed by its sovereign wealth fund, aiming to shield the sector from U.S. tariffs and foreign competition. While the government sees it as a necessary lifeline, critics warn it could stifle private investment and crush smaller players.
Rosenblatt Securities reaffirms a Buy rating on Elastic N.V. (ESTC), citing the company's strategic positioning to capitalize on enterprise AI adoption and platform consolidation, even as it trims its price target to $110 ahead of quarterly results.
Bernstein analysts have raised their price target for IBM following a robust fourth-quarter earnings beat, yet warn the stock's valuation appears stretched as the tech giant navigates AI-driven pressures on its core software and consulting businesses.
William Blair upgrades Palantir Technologies (PLTR) to 'Outperform,' arguing that a recent 30% decline in share price presents a buying opportunity for the AI and data analytics leader, citing strong government and commercial momentum.
Barclays reiterates its Overweight rating on Oracle, citing reduced financial uncertainty after the tech giant outlined plans to raise up to $50 billion. The move is seen as crucial for funding its aggressive push into cloud and AI infrastructure while preserving its credit rating.
